Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Ventral striatal D-3 receptors and Parkinson's disease
Autore:
Joyce, JN; Ryoo, H; Gurevich, EV; Adler, C; Beach, T;
Indirizzi:
Sun Hlth Res Inst, Thomas H Christopher Ctr Parkinsons Dis Res, Sun City, AZ 85351 USA Sun Hlth Res Inst Sun City AZ USA 85351 s Dis Res, Sun City, AZ 85351 USA Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA Mayo Clin Scottsdale Scottsdale AZ USA 85259 le, Scottsdale, AZ 85259 USA
Titolo Testata:
PARKINSONISM & RELATED DISORDERS
fascicolo: 3, volume: 7, anno: 2001,
pagine: 225 - 230
SICI:
1353-8020(200107)7:3<225:VSDRAP>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; CENTRAL PATHOPHYSIOLOGICAL MECHANISMS; NUCLEUS-ACCUMBENS; DOPAMINE-RECEPTOR; BASAL GANGLIA; SUPRANUCLEAR PALSY; MOTOR FLUCTUATIONS; C-11 RACLOPRIDE; COMMON MARMOSET; HUMAN FOREBRAIN;
Keywords:
basal ganglia; dopamine; Alzheimer's disease; limbic system; ventral tegmental area;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
61
Recensione:
Indirizzi per estratti:
Indirizzo: Joyce, JN Sun Hlth Res Inst, Thomas H Christopher Ctr Parkinsons Dis Res, 10515 W Santa Fe Dr, Sun City, AZ 85351 USA Sun Hlth Res Inst 10515 W SantaFe Dr Sun City AZ USA 85351 USA
Citazione:
J.N. Joyce et al., "Ventral striatal D-3 receptors and Parkinson's disease", PARKINS R D, 7(3), 2001, pp. 225-230

Abstract

Antiparkinsonian drugs are thought to act largely through the D2 receptor family that includes the D-2 and D-3 receptors. D-2 and D-3 receptors exhibit both complementary and overlapping expression at the macro and cellular level. The D-3 receptor appears to be a primary target of the mesolimbic dopamine system, is highly enriched in expression within the "limbic" striato-pallidal-thalamic loop, and is recognized as bring regulated by dopaminergic activity in distinctly different ways from the D-2 receptor. In Parkinson's Disease it has been determined that loss of dopaminergic innervation results in elevation of the D-2 receptor but reduced levels of the D-3 receptor. In many late-stage Parkinson's Disease patients then is a loss of antiparkinsonian response to L-dopa and other antiparkinsonian drugs that is often correlated with clinical signs for dementia. We have determined that thereduction of D-3 receptor, and not that of the D-2 receptor, is associatedwith the loss of response to L-dopa and other antiparkinsonian drugs. The reduction of D-3 receptor is also related to the presence of dementia. An elevation of D-3 receptors was evident in those Parkinson's Disease cases with continued good response to L-dopa. Thus, we believe that reduced D-3 receptor number is correlated with certain subgroups of Parkinson's Disease and may also be related to a further diminishment in the mesolimbic DA system. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 16:58:36